Tirzepatide for Obesity Treatment and Diabetes Prevention
Ania M. Jastreboff(Yale University), Irina Jouravskaya(Eli Lilly (United States)), Sean Wharton(University of Toronto), Mathijs C. Bunck(Eli Lilly (United States)), John Wilding(University of Liverpool), Louis J. Aronne(Cornell University), Bruno Halpern(Cornell University), Shuyu Zhang(Shanghai Jiao Tong University), Adam Stefański(Eli Lilly (United States)), Nadia N. Ahmad(Eli Lilly (United States)), Carel W. le Roux(University College Dublin), Ramakrishna Battula(Eli Lilly (United States)), Leigh Perreault(Colorado School of Public Health)
Cited by 368
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k
American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity
|Endocrine Practice|2016|1.8k
Inhibition of Food Intake in Obese Subjects by Peptide YY<sub>3–36</sub>
|New England Journal of Medicine|2003|1.6k
Obesity in adults: a clinical practice guideline
|Canadian Medical Association Journal|2020|1.4k